0001127602-21-003495.txt : 20210202
0001127602-21-003495.hdr.sgml : 20210202
20210202161304
ACCESSION NUMBER: 0001127602-21-003495
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210201
FILED AS OF DATE: 20210202
DATE AS OF CHANGE: 20210202
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Zaks Tal Zvi
CENTRAL INDEX KEY: 0001690927
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38753
FILM NUMBER: 21581593
MAIL ADDRESS:
STREET 1: C/O ADAPTIMMUNE THERAPEUTICS PLC
STREET 2: 60 JUBILEE AVE, MILTON PARK
CITY: ABINGDON, OXFORDSHIRE
STATE: X0
ZIP: OX14 4RX
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Moderna, Inc.
CENTRAL INDEX KEY: 0001682852
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 813467528
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 200 TECHNOLOGY SQUARE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 6177146500
MAIL ADDRESS:
STREET 1: 200 TECHNOLOGY SQUARE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
FORMER COMPANY:
FORMER CONFORMED NAME: Moderna Therapeutics, Inc.
DATE OF NAME CHANGE: 20160822
4
1
form4.xml
PRIMARY DOCUMENT
X0306
4
2021-02-01
0001682852
Moderna, Inc.
MRNA
0001690927
Zaks Tal Zvi
C/O MODERNA, INC.
200 TECHNOLOGY SQUARE
CAMBRIDGE
MA
02139
1
Chief Medical Officer
Common Stock
2021-02-01
4
M
0
5000
12.21
A
5000
D
Common Stock
2021-02-01
4
S
0
400
156.16
D
4600
D
Common Stock
2021-02-01
4
S
0
800
157.28
D
3800
D
Common Stock
2021-02-01
4
S
0
400
158.28
D
3400
D
Common Stock
2021-02-01
4
S
0
800
159.20
D
2600
D
Common Stock
2021-02-01
4
S
0
300
160.33
D
2300
D
Common Stock
2021-02-01
4
S
0
300
162.00
D
2000
D
Common Stock
2021-02-01
4
S
0
300
163.07
D
1700
D
Common Stock
2021-02-01
4
S
0
600
164.20
D
1100
D
Common Stock
2021-02-01
4
S
0
200
165.32
D
900
D
Common Stock
2021-02-01
4
S
0
100
171.30
D
800
D
Common Stock
2021-02-01
4
S
0
700
172.86
D
100
D
Common Stock
2021-02-01
4
S
0
100
174.00
D
0
D
Stock Option (Right to Buy)
12.21
2021-02-01
4
M
0
5000
0
D
2027-10-03
Common Stock
5000
169952
D
The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $155.61 to $156.37. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $156.85 to $157.76. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $157.88 to $158.55. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $158.89 to $159.75. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $159.91 to $160.66. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $161.67 to 162.20. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $162.68 to $163.63. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $163.80 to $164.62. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $165.30 to $165.34. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $172.40 to $173.27. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
229,358 of the options will vest over 4 years (25% on the first anniversary of the grant date of October 3, 2017, then quarterly for the next 3 years). 137,614 of the options will vest over 5 years (25% on the second anniversary of the grant date of October 3, 2017, then quarterly for the next 3 years). 91,743 of the options will vest over 6 years (25% on the third anniversary of the grant date of October 3, 2017, then quarterly for the next 3 years).
/s/ Lori Henderson, as Attorney-in-Fact
2021-02-02